Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer
Clinical trial NCT07704177 · RECRUITING
Trial details
- NCT number
- NCT07704177
- Sponsor
- Peking Union Medical College Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-15
- Primary completion
- 2027-04-15
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.